Ekso Bionics (NASDAQ:EKSO) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report released on Saturday morning. The firm issued a hold rating on the stock.

EKSO has been the subject of a number of other research reports. Lake Street Capital dropped their price objective on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. HC Wainwright cut their price target on shares of Ekso Bionics from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th.

Ekso Bionics Price Performance

Shares of NASDAQ:EKSO opened at $0.58 on Friday. The company’s fifty day moving average is $0.80 and its 200 day moving average is $1.00. The company has a quick ratio of 2.14, a current ratio of 2.81 and a debt-to-equity ratio of 0.28. Ekso Bionics has a 52 week low of $0.50 and a 52 week high of $3.13. The stock has a market cap of $12.76 million, a PE ratio of -0.89 and a beta of 1.43.

Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Monday, October 28th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The company had revenue of $4.13 million during the quarter, compared to the consensus estimate of $6.00 million. During the same period last year, the firm posted ($0.24) EPS. Research analysts anticipate that Ekso Bionics will post -0.48 earnings per share for the current year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.